Gene Therapy: Page


  • Image attribution tooltip
    Gilead Sciences Inc.
    Image attribution tooltip

    Gilead reaches deal for Yescarta coverage in England

    For now, the CAR-T therapy will be provided through NHS' Cancer Drugs Fund, after a government agency judged it too pricey for routine coverage.

    By Ned Pagliarulo • Oct. 5, 2018
  • Image attribution tooltip
    Elizabeth Regan/BioPharma Dive
    Image attribution tooltip

    Sarepta gene therapy for DMD takes another step forward

    Updated results, including data from a fourth boy with Duchenne muscular dystrophy, help to firm up the prospects for the biotech's gene therapy.

    By Ned Pagliarulo • Oct. 4, 2018
  • Trendline

    Gene Therapy

    Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges. 

    By BioPharma Dive staff